ReviewHeart failure reviews2025
Toward next-generation BNP/NT-proBNP biosensors: multiplexed detection, biofouling control, and digital health integration.
Review in Heart failure reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past five years, rapid progress has been made in biosensor platforms for BNP and NT-proBNP detection. Innovations span fluorescence-based assays (FRET aptasensors, quantum dots, NIR persistent luminescence probes), colorimetric nanozyme-enhanced lateral flow assays, surface-enhanced Raman scattering (SERS) systems and electrochemiluminescence immunoassays. These strategies exploit advances in nanomaterials, photonic engineering, and biointerface design to achieve femtogram-to-picogram limits of detection, multiplex biomarker analysis, and smartphone-compatible readouts. Parallel work on biofouling mitigation through zwitterionic coatings, hydrogel nanocomposites, and MOF encapsulation can be adapted for further enhance sensor robustness in complex biological fluids. This review critically evaluates BNP/NT-proBNP detection technologies reported between 2020 and 2025, comparing analytical performance, material design, and translational potential. We highlight gaps between laboratory performance and clinical implementation, discuss harmonisation with established commercial assays, and outline future directions in multiplexed panels, wearable monitoring, and digital health integration. By synthesizing recent advances, this work provides a roadmap toward biosensors capable of transforming HF care through earlier diagnosis, decentralised testing, and proactive disease management.
Indexed as
Identifiers
41329346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.